Zamaporvint

Zamaporvint (RXC004) is an orally active and selective inhibitor of Wnt. Zamaporvint targete membrane-bound o-acyltransferase Porcupine and inhibited Wnt ligand palmitoylation, secretion, and pathway activation. Zamaporvint displays a favorable pharmacokinetic profile and shows potent antiproliferative effects in Wnt ligand-dependent colorectal and pancreatic cell lines. Zamaporvint possesses multiple antitumor mechanisms and can be used in cancer research[1].

Product Specifications

CAS Number

[1900754-56-4]

Product Name Alternative

RXC004

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Acyltransferase; Porcupine; Wnt

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/zamaporvint.html

Purity

99.76

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(CN1C=NC(C2=CC(C(F)(F)F)=NC=C2)=C1C)NC3=NC=C(C4=CN=CC=N4)C=C3

Molecular Formula

C21H16F3N7O

Molecular Weight

439.39

Precautions

H302, H315, H319

References & Citations

[1]Phillips C, The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand-dependent Cancer Models. Cancer Res Commun. 2022 Sep 2;2 (9) :914-928.